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Abnormal accumulation of amyloid beta-peptide (A-beta) is believed to be the 
primary event in the pathogenesis of Alzheimer’s disease (AD). Two cellular 
mechanisms could contribute to the abnormal accumulation of Aβ in the brain: 
over production and/or failure in clearance of this A-beta peptide. In an effort to 
identify the cellular system that is involved in A-beta clearance, we conducted 
experiments to investigate the effects of calpain inhibitors on the production of 
secreted A-beta and the intracellular accumulated derivatives of APP, using a 
culture cell model. Our results revealed that at low concentration, calpain 
inhibitors caused an increase in the accumulation of both A-beta 40 and A-beta 
42. At high concentration, calpain inhibitors led to a decline in A-beta 
accumulation toward the basal level and an increase in intracellular accumulation 
of C-terminal fragments, including CTF-beta, CTF-alpha, generated by beta– and 
alpha-cleavage, respectively. These results suggest that calpain enzymes, which 
are a highly conserved superfamily of calcium dependent papain-like cysteine 
proteases, are involved in the metabolism of APP and the formation and 
accumulation of A-beta. To further identify the enzyme(s) that is responsible for 
calpain inhibitor-regulated A-beta formation and accumulation, we employed the 
small interference RNA (siRNA) approach to investigate the effect of knockdown 
of calpains on the formation and accumulation of A-beta. Our results suggest that 
different isoforms of calpain enzymes may function differently in A-beta 
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production and accumulation. This information may lead to a better 
understanding of the mechanism underlying the abnormal accumulation of A-
beta peptide in the Alzheimer’s disease brain and provide new insight into the 
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Alzheimer’s disease and its two pathological hallmarks  
Alzheimer's disease (AD), also called Alzheimer disease or simply Alzheimer's, is 
the most common cause of dementia. Alzheimer's is a degenerative and terminal 
disease for which there is no known cure. In its most common form, it afflicts 
individuals over 65 years old, although a less prevalent early-onset form also 
exists. Only 10% of early-onset AD are due to rare, fully penetrant (autosomal 
dominant) mutations in 3 genes: Aβ precursor protein (APP) on chromosome 
21[32], presenilin 1 (PS1) on chromosome 14[33], and presenilin 2 (PS2) on 
chromosome 1[34-35]. On the other hand, most cases of AD are later in onset 
(  65 years of age), are nonfamilial, and are probably due to highly prevalent 
genetic variants with low penetrance. [36]  
In 1906 at a meeting in Munich, a German psychiatrist, Alois Alzheimer first 
came up with the definition of a clinicopathological syndrome, which was later-on 
named after his name as Alzheimer’s disease (AD). The characteristics of this 
disease include progressive memory impairment; disordered cognitive function; 
altered behavior including paranoia, delusions and loss of social appropriateness; 
and a progressive decline in language function. He also discovered two distinct 
lesions in AD patients’ brains: intracellular neurofibrillary tangles (NFT) and 
extracellular amyloid plaques (also known as senile plaques or neuritic plaques). 
Clinical science did not make any progress in defining the pathogenesis of this 
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disease until half a century later. Thanks to the advent of electron microscopy, in 
1960s Michael Kidd in England and Robert Terry in the United States were able 
to describe the remarkable ultrastructual changes associated with the two distinct 
lesion which Alzheimer had described. In the mid 1970s, researchers found that 
neurons synthesizing and releasing acetylcholine underwent variable but usually 
severe degeneration. Consequently, pharmacological research made great 
efforts to increase acetylcholine levels in the synaptic cleft, mainly through 
inhibiting the degradative enzyme. However, these cholinergic drugs more often 
ended up with a lack of robust clinical benefit in most patients This lack of clinical 
benefit was most likely due to the degeneration involving highly heterogeneous 
classes of neurons which was discovered later in the early 1980s. Since then, 
attention focused on trying to identify the underlying mechanisms for the synaptic 
dysfunction and perikaryal degeneration, by studying the two characteristic 
neuropathological lesions, senile plaques and neurofibrillary tangles, which have 
been regarded as two hallmarks of AD. [1] 
 
Neuritic plaques are approximately spherical, extracellular deposits of β-amyloid 
proteins (Aβ) fibrils closely surrounded by dystrophic axons and dendrites [2] The 
majority of Aβ is in the form ending at amino acid 40 (Aβ40). A small portion of 
Aβ ends at amino acid 42 (Aβ42) [1,9]. Aβ42, which is slightly longer than Aβ40, 
is a more hydrophobic form that is particularly prone to aggregation. [3] Evidence 
was found that in an AD-specific process. The initial deposition of Aβ42 is 
followed by growth of the amyloid with precipitation of soluble Aβ40. The 
 3
resulting neuritic plaques become increasingly associated with activated 
microglia and reactive astrocytes. Those microglia and astrocytes produce a 
number of molecules such as cytokines, reactive oxygen and nitrogen 
intermediates and proteases that may be toxic to neuronal processes near 
neuritic plaques. They also generate factors that result in reciprocal activation 
and growth, which possibly triggers a local inflammatory cascade. [32] 
 
The neurofibrillary tangles are made up of a protein called tau, which is an 
abnormally phosphorylated protein component of paired helical filaments (PHF) 
and interacts with neuronal microtubles. [4]. According to recent biochemical and 
animal model studies, the affinity of tau for microtubles is weakened by abnormal 
phosphorylation, which leads to the aggregation of tau into filaments and tangles. 
Early steps of this process show toxicity to the neuron, which might be 
exacerbated by tangle formation. [5, 6] 
 
Hypotheses on the underlying mechanism of AD 
The tau tangle hypothesis focuses on the role of tau tangle in the pathogenesis 
of AD, as there is good correlation between NFT numbers and the severity of the 
disease. However, the later appearance of NFTs in the brains of AD patients and 
the evidence that transgenic mice over-expressing mutant tau did not induce 
amyloid plaque formation substantially weaken this point. [8] Now tau tangles are 
more commonly accepted as a downstream factor rather than the origin of AD. 
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The amyloid hypothesis (also known as amyloid cascade hypothesis or Aβ 
hypothesis) was first proposed by D.J.Selkoe and J.A.Hardy in early 1990s, [12, 
13]  based on the facts that the gene encoding APP was mapped to chromosome 
21.[14-16] and Downs syndrome patients with triple chromosome 21 always 
develop the neuropathology of AD[17]. The amyloid hypothesis states that 
abnormal accumulation of Aβ is the primary causative event in the pathogenesis 
of AD [10, 18, 32] 
 
Although this hypothesis has not been universally accepted, there is substantial 
evidence supporting this theory. 1) APP mutations at or near the β-, γ-, or α- 
cleavage sites enhance either total Aβ production or the increase in the more 
toxic form of Aβ42 [19-21]; 2) mutations in presenilin 1 and 2  that lead to AD 
also promote Aβ42 production [23] ; 3) Genetic variability in Aβ catabolism may 
increase the risk of late-onset AD [28]  
 
Therefore, the process of AD probably follows an” amyloid accumulation and 
deposition—tau hyperphosphorylation—tangles formation---neuron death “outline. 
Great efforts aimed at reducing Aβ level are being carried out by pharmacological 
research [33] based on this theory. 
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The processing of amyloid precursor protein and Aβ production 
APP  
Amyloid precursor protein is a large type I transmembrane protein. APP gene 
has been cloned and localized in chromosome 21 [14]. Processed by sequential 
enzymatic hydrolysis at β-, ε-, ζ- and γ- cleavage sites, APP could generate 
Aβ40/42 whose abnormal accumulation would induce AD. There are two 
mutations immediately before the β-cleavage site, call Swedish mutation, which 
tends to favor β-secretase cleavage, thus promote the production of Aβ peptides. 
 
γ-secretase complex 
Presenilin, nicastrin (NCT), APH-1, and PEN-2 form an active γ-secretase 
complex. Presenilin 1 (PS1) undergoes endo proteolytic processing within its 
large cytosolic loop between TM6 and TM7, generating NTF and CTF which 
remain bound together forming a stable, heterodimeric PS complex. Primary 
neurons from PS1 deficient mice showed significantly decrease in Aβ production 
[27] 
 
Amyloidogenic and non amyloidogenic pathways 
APP can be processed in two pathways [Fig.1]. One is non-amyloidogenic 
through α-secretase cleavage, producing membrane-anchored C terminal 
fragment (CTFα) and Soluble APPα (sAPPα). The other is amyloidogenic 
through β-secretase cleavage, producing sAPPβ and CTFβ. For both pathways 
there would be involvement of γ-secretase, which cleaves CTFα into APP 
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Intracellular Domain (AICD, also known as CTFε) and p3, and cleaves CTFβ into 
Aβ peptides and CTFε. [1] 
 
The majority of Aβ produced by β- and γ-secretase are Aβ40 and Aβ42. 
Sequence analysis reveals that there are 7 to 9 amino acids’ distance between 
the N-terminus of CTFε (also known as AICD) and the C terminus of Aβ40/42. 
This results in the identification on a novel cleavage site of APP between Aβ49 
and Aβ50, a ε–cleavage site. Currently, the cleavage at Aβ40/42 has been 
specifically referred to as γ-cleavage site [7,15,17] 
 
Four years ago, a new intracellular long Aβ containing residues 1-46 (Aβ46) was 
identified and known to be produced from the hydrolysis at a novel ζ–cleavage  
 
  
Figure 1:  APP processing mediated by α, β and γ secretases       
AICD is also known as CTFε 
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site, between the known γ- and ε- cleavage sites [18]. Through applying a 
differential inhibition method, Aβ46 has been known to be an intermediate 
precursor of secreted Aβ40/42. Moreover, another long Aβ species, probably 
Aβ49 generated by ε-cleavage, has also been identified. Further analysis showed 
that γ- cleavage is dependent on ζ–cleavage during the proteolytic processing of 
APP. Therefore, a conclusion was reached that a series of sequential cleavages 
together generate secreted Aβ from APP [Fig.2]. Aβ46 could be produced by ζ–
cleavage from ε-cleavage generated Aβ49, and then could be cleaved at the γ- 
cleavage site, releasing Aβ40/42 [20]. This proposed pathway provides us 
explanation on how γ- cleavage occurs in a sequence found in the middle of a 




Figure 2: sequential cleavages in APP processing 
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Calpains and Aβ accumulation 
Calpains are a highly conserved superfamily of calcium dependent papain-like 
cysteine proteases, with two ‘classical’ members, calpain 1 and 2. These two 
proteins are also known as μ-calpain and m-calpain respectively, after their Ca2+ 
sensitivity in vitro (the former being activated at levels of micromoles per litre and 
the latter by millimoles per litre of Ca2+) [22]. Both calpains share similar 
mechanism of activation, with binding of multiple Ca2+ ions disrupting the salt 
bridges that keep the catalytic domain II in an open conformation [23]. Once 
disrupted by Ca2+, the previously open conformation closes up, thereby initiating 
proteolytic activity. Shortly after substrate cleavage, there is also autolytic activity, 
which results in loss of calpain enzymatic activity after only a few minutes.  
It is reported that calpains target tau and amyloid precursor protein. In a 
transgenic model of AD, normal cognition and synaptic transmission has been 
shown to be restored through calpain inhibition [24]. Moreover, an increased 
amount of calpain 2 has been found in extracts from AD patients’ brains, 
localizing to the cytosolic fraction and in neurofibrillary tangles [25].  It has been 
suggested that some of the calpain inhibitors can modulate the production of Aβ, 
possibly through influence on γ-secretase mediated processing of APP [26]. 
However, the reported observations of the effects of the calpain inhibitor on the 
formation of Aβ are still controversial [28, 29, 30] 
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Here we propose that the calpain enzyme is involved in metabolism of APP, 
especially in the process of degradation on secreted Aβ and the intracellular APP 
derivatives. 
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Materials and Methods 
Reagents. 
MDL28710 (carbobenzoxy-valinyl-phenylalaninal also known as calpain inhibitor 
III) [Fig.3], was obtained from Calbiochem and dissolved in dimethyl sulfoxide. 
Aβ40 and Aβ42 were purchased from American Peptide. siRNAs and HiPerFect 
Transfection Reagent were ordered from Qiagen, dissolved in siRNA suspension 
Buffer. Monoclonal antibody 6E10 (Signet Laborotories, Inc.) recognizes residues 
1-17 of the Aβ sequence. Monoclonal APP N-terminal-specific antibody 22C11 
was from Boehringer. Monoclonal anti-actin antibody was from Sigma. Polyclonal 




Figure 3: Molecular formula of MDL28170 
 MDL28170 is a membrane-permeable cysteine protease inhibitor which potently inhibits 
calpain. This compound has been shown to be neuroprotective in vivo and in vitro models of 
ischemic and excitotoxic injury. 
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RNA interference  
RNA interference (RNAi) is a mechanism that inhibits gene expression at the 
stage of translation or by hindering the transcription of specific genes. Small 
interfering RNA strands (siRNA) are keys to the RNAi process, and have 
complementary nucleotide sequences to the targeted RNA strand. Specific RNAi 
pathway proteins are guided by the siRNA to the targeted messenger RNA 
(mRNA), where they "cleave" the target, breaking it down into smaller portions 
that can no longer be translated into protein. 
 
Cell culture  
N2a cells, expressing wild-type presenilin 1 (PS1wt) and Swedish mutant APP 
(APPsw), were kindly provided by Drs.Sangram S.Sisodia and Seong-Hun Kim 
(University of Chicago) and maintained as described previously [31].  Opti-MEMI 
media were applied, with enhanced growth factor. Sixteen hours after splitting, 
the old Opti-MEMI medium containing 10% FBS was replaced with fresh Opti-
MEMI containing 0.5% FBS. Twenty-four hours after that, the cells were either 
treated with or without inhibitors for 12 hours, or splitted again and treated with or 
without siRNA complex for the time periods indicated. 
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Immunoprecipitation and Western blot analysis 
Immunoprecipitation and Western blot analyses were carried out as described 
previously [18]. To determine the intracellular APP derivatives, cells were 
harvested and lysed in Western blot lysis buffer (50mM Tris-HCl, pH6.8, 8Murea, 
5% β-mercaptoethanol, 2% SDS, and protease inhibitors). Secreted Aβ was 
immunoprecipitated from conditioned media using a monoclonal Aβ-specific 
antibody 6E10 (Signet Laborotories, Inc.). Both cell lysates and 
immunoprecipatates were analyzed by 11% Bicine/urea SDS-PAGE, or 10%-
16% regular SDS-PAGE, and transferred to a polyvinylidene fluoride membrane 
(Immobilon-P, Millipore). The membranes were then probed with specific 






Part I: Treatment with inhibitors 
N2a cells stably expressing both wild-type PS1(PS1wt) and myc-tagged Swedish 
mutant APP (APPsw), which have been used in previous studies were treated 
with MDL28170 or MG132 at various concentrations for 12 h in Opti-MEM 
containing 0.5% FBS. After that, conditioned media and cell lysates were 
analyzed by SDS-PAGE.  
 
MDL28170 caused an increase in amyloid-β peptides at low concentrations and 
a decrease at high concentrations. 
The conditioned media was processed by immunoprecipitation. Then was 
analyzed by 11% urea-SDS-PAGE (fig.4_A). At low concentrations (up to 10μM), 
MDL28170 caused a dose-dependent increase in secreted Aβ40. At high 
concentrations (from 20 to 40μM), the increased Aβ40 showed a declining trend, 
back to its basal level.   
 
MDL28170 caused intracellular accumulations of C-terminal fragments  
Cell lysates were analyzed by regular 10-16% SDS-PAGE, probed with C15 
(fig.4_D, F) and 6E10 (fig.4_E) antibodies. At low concentration, MDL28170 
caused slight increase in the level of CTFα and CTFβ. At hight concentration, 
MDL28170 caused a mark increase in the level of both CTFα and CTFβ. For 
CTFε, an increase was observed at low concentration of MDL28170. However, at 
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Figure 4: The effects of MDL28170 on APP derivatives 
Western blot results:  A) Secreted Aβ40 immunoprecipitated from conditioned media 
ananlyzed by 11% urea-SDS-PAGE and probed by 6E10; B) Conditioned media analyzed by 
10% SDS-PAGE and probed by 6E10; C) Conditioned media analyzed by 10% SDS-PAGE 
and probed by 22C11; D) Cell lysates analyzed by 10-16% SDS-PAGE and probed with C15; 
E) Cell lysates analyzed by 10-16% SDS-PAGE and probed with 6E10; F) Prolonged 
exposure of (D); G)Cell lysates analyzed by 10% SDS-PAGE and probed by anti-actin as 
loading control. The antibody specificity: Monoclonal antibody 6E10 recognizes residues 1-
17 of the Aβ sequence. Monoclonal antibody 22C11 recognizes the N-termini of APP. 
Polyclonal antibody C15 is raised against the C-terminal 15 residues of human APP 
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high concentration of MDL28170, the accumulation of CTFε declined. 
 
MDL28170 hardly had any affect on the production of soluble APPα and soluble 
APPβ. 
A small portion of conditioned media were analyzed by 10% SDS-PAGE directly. 
(fig.4_B, C). Here the amount of soluble APPα and soluble APPβ were 
unchanged across different dosages of calpain inhibitors.  
 
Proteasome inhibitor MG132 has no effect on the accumulation of Aβ and other 
APP derivatives. 
To determine whether the MDL28170 caused accumulation of Aβ is due to non-
specific inhibition of proteasomal degradation, cells were treated with 
proteasome inhibitor MG132. Conditioned media, processed by 
immunoprecipitation first, were analyzed by 11% urea-SDS-PAGE. As shown in 
Fig. 5A, there is no increase in Aβ level was observed in MG132-treated cells 
 
When cell lysates were analyzed by regular 10-16% SDS-PAGE (fig.5_B), it was 
observed that the amount of intracellular accumulation of C-terminal fragments 
was approximately constant across different dosages of MG132. 
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Figure 5: The effect of MG132 on APP derivatives  
Western blot results: A) Secreted Aβ40 immunoprecipitated from conditioned media 
ananlyzed by 11% urea-SDS-PAGE and probed by 6E10; B) Cell lysates analyzed by 10-
16% SDS-PAGE and probed with C15; C)Cell lysates analyzed by 10% SDS-PAGE and 
probed by anti-actin as loading control. The antibody specificity: Monoclonal antibody 6E10 
recognizes residues 1-17 of the Aβ sequence. Polyclonal antibody C15 is raised against the 








Part II: Treatment with siRNA 
N2a cells stably expressing both wild-type PS1(PS1wt) and myc-tagged Swedish 
mutant APP (APPsw), which have been used in previous studies, were treated 
with calpain-specific siRNA complexes. Cells were cultured in DMEM containing 
10% FBS for the time periods indicated. After that, conditioned media and/or cell 
lysates were analyzed by SDS-PAGE. Control 1 was treated with non-silence 
siRNA complexes while control 2 was treated with only HiPerfect delivering 
reagent. 1 and 2 for each kind of calpain specific siRNA represents different 
targeted domains.[Fig.6] 
 
Cells treated by μ-calpain-specific siRNA show significant increase in CTFα after 
3 or 4 days’ treatment. 
Cell lysates were analyzed by regular 10-16% SDS-PAGE. (fig.6)The levels of 
CTFα were almost the same among different groups after 2 days’ treatment. 
After 3 or 4 days, the CTFα levels for μ-calpain group demonstrated significant 
increase. 
 
Knocking down m-calpain levels tends to cause an increase in secreted amyloid-
β peptides (3 days’ treatment) 
The majority of conditioned media was first processed by immunoprecipitation, 
and then was analyzed by 11% urea SDS-PAGE. (fig.7_A), m-calpain siRNA 




Figure 6: Preliminary experiments indicated calpain-specific siRNA effects 
the accumulation of CTFα after 3 or 4 days’ treatment 
Western blot results: Cell lysates analyzed by 10-16% SDS-PAGE and probed with C15. The 
time listed beside the figures indicated how long the cells were treated with siRNA 
complexes. The antibody specificity: Polyclonal antibody C15 is raised against the C-terminal 







Figure 7: The effects of different calpain-specific siRNA on APP derivatives 
Western blot results: A) Secreted Aβ40 immunoprecipitated from conditioned media 
ananlyzed by 11% urea-SDS-PAGE and probed by 6E10; B) Cell lysates analyzed by 10-
16% SDS-PAGE and probed with C15; C) Prolonged exposure of (B); D) Conditioned media 
analyzed by 10% SDS-PAGE and probed by 6E10;  E) Conditioned media analyzed by 10% 
SDS-PAGE and probed by 22C11; F) Cell lysates analyzed by 10-16% SDS-PAGE and 
probed with 6E10; G) Cell lysates analyzed by 10% SDS-PAGE and probed by anti-actin as 
loading control. The antibody specificity: Monoclonal antibody 6E10 recognizes residues 1-
17 of the Aβ sequence. Monoclonal antibody 22C11 recognizes the N-termini of APP. 
Polyclonal antibody C15 is raised against the C-terminal 15 residues of human APP 
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Knocking down μ-calpain levels causes intracellular accumulations of CTFα (3 
days’ treatment) 
Cell lysates were analyzed by regular 10-16% SDS-PAGE (fig.7_B,C) and 
probed with C15. CTFα levels for μ-calpain siRNA group demonstrated 
significant increase compared with the control.  
 
siRNA hardly has any effect on the production of soluble APPα and soluble 
APPβ. (3 days’ treatment) 
A small portion of conditioned media were analyzed by 10% SDS-PAGE directly. 
(fig.7_D,E) Here the amount of soluble APPα and soluble APPβ were constant 
across different groups.  
 
Knocking down calpain levels hardly has any effect on CTFβ and Aβ46 (3 days’ 
treatment) 
Cell lysates were analyzed by regular 10-16% SDS-PAGE (fig.7_F) and probed 




In cells either treated by calpain inhibitors or calpain-specific siRNA complexes, 
neither of the α- and β- secretase mediated APP processing steps are affected. 
In non-amyloidogenic pathway, APP would be cleaved by α- secretase, 
producing sAPPα and CTFα. CTFα undergoes γ- secretase-mediated processing, 
while sAPPα is hardly subjected to any further proteolysis. Therefore, the level of 
sAPPα could be considered as a good indicator of the activity of α- secretase-
mediated APP processing (non-amyloidogenic pathway). Because sAPPα levels 
were approximately the same among different treatment and control groups in 
calpain inhibitors experiments and the siRNA experiments, the α- secretase 
mediated APP processing steps seemed to be unaffected by calpain enzymes. 
 
Similarly, in amyloidogenic pathway the β- secretase mediated APP processing 
steps appeared unaffected by calpain enzymes, too.   
 
Calpain enzymes are involved in the metabolism of APP and the formation and 
accumulation of Aβ 
At low concentration, calpain inhibitor MDL28170 caused a dose-dependent 
increase in Aβ40 in the conditioned media of cultured cells. This increase could 
either caused by increase in Aβ production or decrease in Aβ degradation. As 
what we applied is an enzyme inhibitor, it is very likely that the increase in the 
Aβ40 is the result of inhibition on the degradation of Aβ40. In the same 
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experiment, we also observed that at high concentration of MDL28170, the 
increased Aβ level declined and eventually back to the basal level. It is very 
possible that at high concentration, MDL28170 may not only slow down the 
degradation of Aβ, but also non-specifically inhibit the γ-secretase activity, 
resulting in a decrease in Aβ production. As a result of the inhibition of 
degradation and the inhibition of the production of Aβ40, at high concentration 
(40 μM), MDL28170 showed no effect on the final level of Aβ40.  
 
At low concentration, MDL28170 also protected CTFε from degradation. 
However, in the presence of high concentration of MDL28170, the CTFε was not 
increased, but rather decreased. This result strongly suggests that at high 
concentration, MDL28170 non-specifically inhibit γ-secretase activity resulting in 
reduced production of CTFε. This result is consistent with the effects of 
MDL28170 on the accumulation of Aβ. 
 
CTFα and CTFβ, which are substrate of γ-secretase mainly undergo γ-secretase 
processing, while a portion of them are also subjected to degradation. As shown 
in the panel D and E in figure 4, at low concentration, MDL28170 caused a slight 
accumulation of CTFα and CTFβ, suggesting MDL28170 inhibited the 
degradation of these CTFs. However, at higher concentrations, MDL28170 
caused dramatic increase in the accumulation of CTFα and CTFβ. This is 
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apparently a result of the additive effects of the inhibition of both random 
degradation and γ-secretase processing of these CTFs.  
 
It is possible that in our experiment calpain inhibitors block the function of 
proteasomes, which mainly degrade proteins by proteolysis in cells and thus 
leads to the buildup of APP derivatives during proteolytic processing. Here, 
proteasome inhibitor MG132 was applied the same way as MDL28170 was done. 
No increment in the accumulation of intracellular C-terminal fragments was found. 
Neither did the accumulation of Aβ40. Therefore, we can confidently rule out the 
possibility that MDL28170 affects APP metabolism through blocking 
proteasomes. 
 
So, at this step, we can say that calpain inhibitor sensitive enzymes are involved 
in the degradation of APP derivatives produced during proteolytic processing of 
APP. 
 
Our observation that the effect of MDL28170 on the accumulation of Aβ is 
completely dose dependent may provide an answer to the controversial results 
reported by previous studies. Some reports that MDL28170 inhibited the 
formation of Aβ40, while a further study showed that at low concentrations, 
MDL28170 increased Aβ40. Our data demonstrate that the effect, either an 
enhancing or an inhibiting effect, of MDL28170 on the formation of secreted 
Aβ40, is totally dependent on the dose of the inhibitor used. Thus, the conflicting 
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results reported by previous studies may be due to differences in the dose of 
inhibitors used. 
 
Different isoforms of calpain enzymes function differently in Aβ production and 
accumulation  
Various subcellular compartments including the ER, the IC, the Golgi/TGN, 
endosomes/lysosomes, and the cell surface have been demonstrated to be sites 
for Aβ generation. It is known that different Aβ species are generated in distinct 
subcellular compartments, and the sites for generation of intracellular cellular and 
secreted Aβ are also different. This may explain our observation that different 
isofoms of calpain have different effects on the metabolism of different APP 
derivatives.  
 
In the RNAi experiment, the activities of α- and β- secretase mediated APP 
processing are not affected by the treatment of calpain-specific siRNA. Thus, the 
finding that the knock down of the level of μ-calpain enzyme leads to the 
accumulation of CTFα and CTFε, without affecting Aβ or CTFβ levels, may 
reasonably indicate that degradation of CTFα and CTFε in the non-
amyloidogenic pathway is closely related with μ-calpain enzyme. 
 
On the other hand, the knock down of the level of m-calpain enzyme resulted in 
the Aβ40 accumulation without affecting C-terminal fragments or intracellular 
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Calpain plays an active role in APP processing and metabolism. As there are no 
specific inhibitors for calpains, we first used a potent inhibitor MDL28170 to 
investigate the relationships and speculated its inhibitory effect on APP 
derivatives. To further identify the enzyme(s) that is responsible for calpain 
inhibitor-regulated Aβ formation and accumulation, we applied the siRNA 
approach to investigate the effect of knockdown of calpains on the formation and 
accumulation of Aβ. Our results suggest that m-calpain enzyme may be involved 
in the degradation of secreted Aβ40, while μ-calpain may be involved in the 
degradation of intracellular C-terminal fragments produced in the non-
amyloidogenic pathway. This information may lead to a better understanding of 
the mechanism underlying the abnormal accumulation of Aβ peptide in the 
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